6
NEWS
AID systems for T2D
A secondary analysis of a clinical trial has shown that Automated Insulin
Delivery (AID) systems (known outside of the US as HCL - hybrid closed
loop) lower HbA1c levels and increase the percentage of time in range
in adults with Type 2 diabetes, regardless of their Cpeptide level (data
from the Centers for Medicare & Medicaid Services, or CMS in the US)
requires a low Cpeptide level in order to obtain finance coverage for
insulin pumps, which prevents many patients w from obtaining insurance
coverage for AID systems).
Researchers performed a secondary analysis of a clinical trial in which
254 adults with insulin-treated T2D were randomly assigned to either
receive AID systems or continue their prior insulin delivery method with
realtime continuous glucose monitoring (control group). Changes in
HbA1c level and other glycaemic parameters from baseline to 13 weeks
were assessed for high and low C-peptide subgroups.
In the AID group, the mean HbA1c level decreased by 0.8% from
baseline - a significantly greater reduction than in the control group
for both the high and low Cpeptide subgroups. The AID group also had
higher percentages of time in range than the control group for both high
and low C-peptide levels.
T1D worse in young
The BBC reports that scientists have
discovered why Type 1 diabetes is
more severe and aggressive when
it develops in young children. A
research team has shown that
the pancreas is still developing in
childhood, particularly under the
age of seven, making it far more
vulnerable to damage.
They say newly developed drugs
could buy patients time for the
pancreas to mature, delaying the
disease.
To find out more, CLICK HERE.
Sixth comic
released
The latest T1D comic book from
Revolve Comics - the sixth in the
series - has just been released, to
mark World Diabetes Day. Entitled
Alive and Pumped, the comic book
is free to download (see link at end).
This time, it covers prediction of Type
1 diabetes, antibodies and the future
exciting world of immunotherapy,
as well as the recent huge rise in the
number of people using wearable
diabetes technology. The comic
book follows Aiko, a young hero who
she finds herself in both of these
situations and sees the true power
of insulin combined with technology
first-hand. With input and direction
from diabetes consultants Mayank
Patel and Partha Kar.
To download, CLICK HERE.
Hydrogel for weight-loss?
Sirona, an oral gastro-retentive hydrogel, has been found to produce
sustained reductions in body weight and dietary intake, with only mild
gastrointestinal side effects. Hydrogels, valued for their biochemical
inertness, are being explored for obesity treatments. Sirona is a polymer
that expands in the stomach and has demonstrated appetite suppression
and multiday gastric retention in a first-in-human prospective study.
Researchers conducted a randomized UK trial to assess the feasibility,
tolerability, safety, and preliminary efficacy of Sirona in adults aged 18-65
years with a BMI of 30-40. The participants were randomly assigned in a
3:1 ratio to receive either Sirona or a placebo for 12 weeks, followed by a
12-week extension during which all received Sirona.
At 12 weeks, mean total body weight loss was greater with Sirona than
with the placebo, with continued weight loss observed at 24 weeks. Mean
daily dietary intake decreased by 382.5 kcal at 12 weeks in the Sirona
group and was maintained at 24 weeks. No serious adverse events were
reported. Mild gastrointestinal effects were the most common and did
not require medical intervention.
"Sirona has potential as a nonpharmacological treatment for
weight management, encompassing initial weight loss and weight-loss
maintenance through long-term use, to be tested in larger trials," the
authors wrote.